EKF Diagnostics Holdings (LSE:EKF) has kept its full-year expectations on track after reporting wider gross margins in the first half of 2026, even as revenue held broadly flat. The point-of-care diagnostics group, which published interim results on 15 September 2026, said it expects revenue and adjusted EBITDA growth for the full year in line with market expectations, placing more weight on delivery in the second half.

What the company does

Headquartered in Cardiff, EKF Diagnostics develops, manufactures and sells diagnostic products. Its business is split into two divisions. Point-of-Care covers analysers and consumables for haemoglobin testing, including the DiaSpect and HemoPoint ranges, and diabetes testing. Life Sciences includes the company's beta-hydroxybutyrate (β-HB) reagent business, fermentation services and contract manufacturing, with significant operations in Indiana in the United States.

Latest developments

Revenue for the six months to 30 June 2026 was £25.0 million, compared with £25.2 million a year earlier. Point-of-Care revenue slipped 3% to £15.0 million, with the company saying that the timing of orders and tenders pushed some revenue into the second half. Life Sciences grew 8% to £10.0 million, helped by a 14% rise in fermentation and a 25% increase in contract manufacturing. By region, the Americas were flat at £12.9 million while Asia-Pacific grew 10%.

Operationally, EKF fully exited its former Elkhart, Indiana site on 30 June, a year ahead of schedule, at a one-off cost of £0.3 million, concentrating fermentation at its South Bend facility. The DiaSpect haemoglobin product is being refocused on US blood banks, and a master service agreement with the BCA network was signed in March. A dedicated US sales team for β-HB is also working with distribution partners. Chief executive Gavin Jones said holding steady in a challenging market showed the resilience of the product portfolio, and expressed confidence in growth from Point-of-Care haematology in the second half.

Financial and dividend picture

Gross profit rose to £13.3 million, lifting gross margin to 53.0% from 50.2% thanks to a richer product mix. Adjusted EBITDA edged up 2.4% to £5.9 million, while profit before tax was £3.4 million against £3.6 million. Basic earnings per share rose to 0.54p from 0.43p. Net cash from operations was £3.3 million and cash stood at £16.0 million, including £2.4 million held in Russia subject to restrictions. No dividend was paid or declared in the period, but the company continued its share buyback, repurchasing 3.55 million shares for £0.9 million. Full-year consensus cited by the company stands at £54.6 million of revenue and £13.6 million of adjusted EBITDA.

Sector and index context

EKF is a constituent of the FTSE AIM All Share Index, which includes a cluster of smaller healthcare and diagnostics companies. The sector has faced normalising demand after the pandemic period, pricing pressure in some markets and a focus on cash generation, with investors favouring businesses able to show steady margins and self-funded growth.

Key risks

The full-year outcome depends on an improved second half, particularly in Point-of-Care, leaving the company exposed to tender timing and order delays. A large share of revenue comes from the Americas, adding currency and US market risks. Cash held in Russia remains restricted, and competition in diagnostics is intense.

What to watch next

Investors will look for a trading update around the year end confirming whether second-half delivery has matched expectations, and for progress with US blood banks and the β-HB sales effort. The company has also reiterated its five-year target of more than £80 million in revenue and £20 million in adjusted EBITDA by 2029, so updates on that plan will be closely followed.